cogitation objectives: To evaluate the efficiency and reproducibility of pulmonary delivery of an investigational tobramycin PulmoSphere formulation (PStob) [Inhale Therapeutic Systems; San Carlos.

cogitation objectives: To evaluate the efficiency and reproducibility of pulmonary delivery of an investigational tobramycin PulmoSphere formulation (PStob) [Inhale Therapeutic Systems; San Carlos, CA] from a passive dry powder inhaler, and to compare serum concentrations and whole-lung deposition with a commercial nebulized tobramycin consequence (TOBI; Chiron Corporation; Seattle, WA).

Design: A five-period, open-label, nonrandomized crossover study

Participants: Fourteen healthy presents were studied, and 12 complet the study

Interventions: PStob pulverize was manufactured using lipid-based PulmoSphere technology, producing highly dispersible porous particles. PStob was radiolabeled with [sup99m]Tc and in vitro experiments confirmed it as a valid physic marker. To identify whole-lung distribution via scintigraphy, make submissives inhaled contents of a single capsule (72 L/min) containing 25 mg of [sup.99]Tc-labeled PStob (135 mg of tobramycin liberated base) in periods 1 to 3 In period 4 enthralls received [sup.99m]Tc nebulized tobramycin, approximately 25 mL of 300 mg/5 mL Deposition and relations samples were obtained. In period 5 six 25-mg doses of unlabeled PStob (81 mg of tobramycin base) were inhaled and posterity samples were collected.

Measurements and results: Mean whole-lung deposition of PStob was 34 [+ or -] 6% and nebulized tobramycin was 5 [+ or -] 2% Peak tobramycin concentration in serum (Cmax) values were 06 [micro]g/mL with PStob and 028 [micro]g/mL after nebulized tobramycin. Serum area in a less degree than the curve was 4.4 [micro]g x h/mL v 21 [micro]g x h/mL for nebulized tobramycin. Median time to Cmax for PStob was comparable to nebulized tobramycin.

Conclusions: The aerosol doses of PStob (25 mg and 150 mg) were well dispersed and tolerated. Serum put drugs into concentrations matched scintigraphy data and were roughly twice that of the comparator. Intrasubject dose variability for three equivalent periods did not exce 18% relative SD PStob Cmax (06 [micro]g/mL) was well below the toxic commencement (2 [micro]g/mL).

fundamental note words: anti-infectives; dry powder inhalation; inhaled tobramycin; nebulization; PulmoSphere; Turbospin

Abbreviations: AUC = area beneath the curve; CF = cystic fibrosis; Cmax = peak tobramycin concentration in serum; CV = coefficient of variation: DPI = craving drink powder inhaler; P/C ratio = ratio of peripheral to central lung deposition; PSD = particle size distribution; PStob = tobramycin PulmoSphere formulation; Tmax = time to peak tobramycin concentration in serum

**********

For > 2 decades, inhaled antibiotics (and antifungal agents) have been used effectively for ameliorating chronic pulmonary infections in conditions like as cystic fibrosis (CF), and non-CF bronchiectasis. Various aerosol delivery devices, of the like kind as dry powder inhalers (DPIs), pressurized metered-dose inhalers, and nebulizers are available for pulmonary mix with drugs administration, each with well-recognized advantages and disadvantages. Nebulization has many well-documented disadvantages, including prolonged administration time, high cost, grave efficiency and poor reproducibility, risk of bacterial contamination, and the ne for massive compressors or gas cylinders. Pressurized metered-dose inhalers usually provide plenteous smaller unit doses than would be considered practical for antibiotic therapy. Administration of antibiotic arid powder aerosols to the lung has been attempted, if it were not that studies (1,2) were limited by way of inefficient delivery devices and/or poorly dispersible lactose formulations.

late particle-engineering technologies, such as the PulmoSphere proces (Inhale Therapeutic Systems; San Carlos, CA), have l to more easily dispersible levigates with improved aerodynamic properties. (3) These gunpowders have been shown to deliver remedys efficiently to the lower respiratory tract using relatively simple and inexpensive DPIs. (4) The objectives of the in every one's mouth study were as follows: (1) to determine the efficiency and reproducibility of pulmonary delivery of an engineered tobramycin pulverized substance aerosol (tobramycin PulmoSphere formulation [PStob]; Inhale Therapuetic Systems) from a simple, portable DPI using pharmacoscintigraphy; and (2) to compare pharmacokinetics and whole-lung deposition with a clinically available nebulized tobramycin fruits (TOBI; Chiron Corporation; Seattle, WA).

MATERIALS AND METHODS

PStob was manufactured using an emulsion-based, spray-drying proces described previously. (5) The emulsion feedstock contains a volatile blowing agent (perfluorooctyl bromide), which aids in the creation of ultralow density sponge-like particles. PStob was inhaled from a Turbospin DPI (PH&T; Milan, Italy). Capsules were filled with 25 mg of PStob dust that contained nominally 90% weight/weight tobramycin sulfate, corresponding to a sway of active tobramycin free base of 135 mg by actuation.

TOBI was obtained from local pharmacy at the clinical investigator; it contains 300 mg of tobramycin delivered base in 5 mL of sodium chloride (225 mg/mL) at pH 60 Nebulized tobramycin was administered as directed using a hand-held PARI LC Plus Nebulizer (PARI GmbH; Starnberg, Germany) in combination with the PARI Master compressor from one side of to the other a period of 15 min, the time praiseed by the manufacturer. The PARI Master compressor has been demonstrated to have comparable performance to the DeVilbiss Pulmoaide (Sunrise Medical; somersault PA), the compressor recommended by dint of the manufacturer of TOBI. (6)

...